International drug regulators have reached a certain degree of alignment on key principles to support the use of adapted COVID-19 vaccines against Omicron variants of concern, but say that the development of such vaccines is made difficult by the rapid arrival of new variants.
Pace Of Omicron Variants Hindering Work On Adapted COVID-19 Vaccines
The European Medicines Agency says regulators are currently discussing the extent to which clinical data will have to be submitted to support the approval of an adapted vaccine against Omicron variants.
More from Europe
More from Geography
• By
The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.